Results 21 to 30 of about 12,593 (182)
Biophysica, 2022 In this work, we studied the effect of as on the interaction of membrane DPPC with the key antifibrotic drug pirfenidone. Liposomal forms of pirfenidone were obtained using passive loading.
Irina M. Le-Deygen +4 more
doaj +1 more source
Role of pirfenidone in the management of pulmonary fibrosis [PDF]
, 2017 Keith C Meyer,1,2 Catherine A Decker3,4 1University of Wisconsin Lung Transplant and Advanced Lung Disease Program, 2Department of Medicine, Section of Allergy, Pulmonary and Critical Care Medicine, Clinical Sciences Center, University of Wisconsin ...
Catherine Decker +3 more
core +1 more source
JCI Insight, 2022 Despite decades of research, there is no specific therapy for acute pancreatitis (AP). In the current study, we have evaluated the efficacy of pirfenidone, an antiinflammatory and antifibrotic agent that is approved by the FDA for treatment of idiopathic
Ejas Palathingal Bava +17 more
doaj +1 more source
Nintedanib, Pirfenidone and the combination
, 2022 Pairwise meta-analysis on nintedanib, pirfenidone and the combination of the ...
Tyler Pitre
core +1 more source
International Journal of Nanomedicine, 2022 Zhaosheng Jiang,1,* Jiahao Wang,2,* Wei Meng,1,* Youlang Zhou,3 Limin Ma,1 Yangbo Guan1 1Department of Urology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, People’s Republic of China; 2Department ...
Jiang Z +5 more
doaj
Respiratory Medicine Case Reports, 2018 We report a case of chronic hypersensitivity pneumonitis treated with pirfenidone in a 76-year-old woman who complained of acute-onset abdominal pain and rashes.
Akihiro Shiroshita +2 more
doaj +1 more source
Pirfenidone: an update on clinical trial data and insights from everyday practice [PDF]
European Respiratory Review, 2014 Pirfenidone is an orally active, small molecule that inhibits synthesis of profibrotic and inflammatory mediators. It was approved for the treatment of adults with mild-to-moderate idiopathic pulmonary fibrosis in the European Union based on the results ...
Michael Kreuter
doaj +1 more source
Tolerability to pirfenidone therapy.
, 2020 Tolerability to pirfenidone therapy.
Zuojun Xu (129186) +4 more
core +1 more source
BMC Pulmonary Medicine, 2018 Background Pirfenidone, a pleiotropic anti-fibrotic treatment, has been shown to slow down disease progression of idiopathic pulmonary fibrosis (IPF), a fatal and devastating lung disease.
M. Molina-Molina +8 more
doaj +1 more source
, 2021 Comparison of cause of pirfenidone discontinuation between patients who were treated with full recommended dose of pirfenidone (1800mg/d) and relatively low dose of pirfenidone (600mg/d or 1200mg/d).
Soon Seog Kwon (11873790) +8 more
core +1 more source